PGLa |
| Catalog No.GC32319 |
PGLa, a 21-residue peptide, is an antimicrobial peptide.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 102068-15-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PGLa is an antimicrobial peptide. PGLa is known to be bacteriostatic against both Gram-positive and Gram-negative bacteria.
PGLa is known to be bacteriostatic against both Gram-positive and Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Streptococcus pyogenes, and Staphylococcus aureus), without much selectivity between the two types of bacterial cells. PGLa is synthesized as a native (the wild type) peptide and as a mutant with a norleucine instead of methionine at position 2Met (designated PGLa(Nle)).
[1]. Radchenko DS, et al. Does a methionine-to-norleucine substitution in PGLa influence peptide-membrane interactions? Biochim Biophys Acta. 2016 Sep;1858(9):2019-27.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *